Oruka Therapeutics (ORKA) SVP Agarwal Arjun Sells $806K of Stock

Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, Inc. (NasdaqGM: ORKA), sold 9,999 shares on October 12, 2026, for approximately $805,888. This transaction was planned in advance, reflecting Agarwal's strategy regarding his holdings in the company.

Inside Agarwal's Trade

Agarwal sold the shares at a price of $80.60 each. This sale comes as Oruka continues to develop its monoclonal antibody therapies for conditions like psoriasis and other inflammatory diseases. The transaction adds to a notable period of insider activity at the company.

Other Institutional Activity in Oruka

FMR, LLC increased its position in Oruka Therapeutics by 1,626,036 shares, bringing its total to 9,057,645 shares worth about $651.5 million. Blackrock Inc. also raised its stake, adding 1,463,053 shares, totaling 4,990,181 shares valued at approximately $358.9 million. Capital World Investors grew its holdings by 1,700,820 shares, ending with 3,401,639 shares worth about $244.7 million. These moves suggest strong institutional interest in Oruka.

Oruka Therapeutics, Inc. Stock Down 1.3%

As of October 16, 2026, Oruka Therapeutics shares were trading recently around $72.91, which is below the 50-day moving average of $93.10 by 21.7%. The stock is also below its 52-week high of $115.52 by 36.9%, indicating a challenging market environment despite the company's innovative pipeline.

Recent Earnings

Oruka Therapeutics reported a trailing twelve-month revenue of $0, as the company is still in the clinical trial phase for its products. The next earnings report is scheduled for November 11, 2026, which will provide further insights into its financial health.

Insider Buying and Selling at Oruka Therapeutics, Inc.

Earlier in June 2026, Agarwal himself bought 9,459 shares at $15.88 each, totaling about $150,175. This contrasts with the recent sale, indicating a shift in his investment strategy. Other insiders, like CEO Lawrence Klein, also sold shares earlier in June, further highlighting recent insider activity.

Analysts Set New Price Targets

On August 11, 2026, Guggenheim reiterated a Buy rating for Oruka with a price target of $200. Wedbush also maintained an Outperform rating with a target of $165. The consensus among analysts is a strong buy, with a mean target price of $155, suggesting potential growth for investors.

About Oruka Therapeutics

Oruka Therapeutics, based in Menlo Park, CA, is focused on developing innovative treatments for psoriasis and other inflammatory conditions. Its lead products are in advanced clinical trials, targeting significant unmet medical needs. The recent insider activity reflects ongoing strategic decisions as the company prepares for future developments.

Bottom Line

Investors should watch for Oruka's upcoming earnings report on November 11, 2026, which could provide crucial updates on its clinical progress and financial outlook. Additionally, the recent insider trades suggest a dynamic environment as company leaders navigate their positions amid ongoing developments.